Enhancing Cancer Therapy: Antibody Drug Conjugates and Immunotherapies for Resistant Cancers

Antibody-drug conjugates (ADCs), which combine monoclonal antibodies with cytotoxic agents, offer a targeted approach to cancer therapy, aiming to deliver drugs directly to tumor cells while minimizing off-target effects. Despite the considerable potential of ADCs, challenges like resistance development and their limited efficacy against solid tumors persist. Recent approaches have explored combining ADCs with immuno-therapies, such as immune checkpoint inhibitors and cellular immune engagers, to enhance the immunogenicity of the tumor microenvironment and promote a stronger immune response against cancer cells.

This Research Topic aims to delve into the innovative integration of ADCs and various forms of immunotherapy to address the existing limitations in cancer treatment. The focus is on the synergistic interactions between these therapies that not only enhance tumor cell eradication but also boost the immune system's response, potentially leading to more durable outcomes and overcoming resistance to conventional treatments. By studying the mechanisms of action, researchers can optimize these combinations to improve efficacy and achieve more durable responses in cancers resistant to single-agent treatments. This effort involves understanding optimal dosing, sequencing strategies, and identifying predictive biomarkers to maximize therapeutic benefit while minimizing toxicity.

To foster advancements in this promising field, this Research Topic will cover a wide array of pertinent themes, including:
o Mechanisms underlying the synergy between ADCs and immunotherapies
o Preclinical and clinical assessments of ADC-immunotherapy combination therapies
o Strategies for optimal dosing and treatment sequencing
o Exploration of resistance mechanisms to combination therapies
o Identification of predictive biomarkers for better patient stratification

We welcome submissions of original research, review articles, and case studies that contribute to these areas. This initiative is intended to propel forward the integration of ADCs with immunotherapy, offering novel therapeutic strategies for patients battling complex cancer types.





Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.

Article types and fees

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Case Report
• Clinical Trial
• Editorial
• FAIR² Data
• FAIR² DATA Direct Submission
• General Commentary
• Hypothesis and Theory
• Methods
• ... View all formats

Articles that are accepted for publication by our external editors following rigorous peer review incur a publishing fee charged to Authors, institutions, or funders.

Article types

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Case Report
• Clinical Trial
• Editorial
• FAIR² Data
• FAIR² DATA Direct Submission
• General Commentary
• Hypothesis and Theory
• Methods
• Mini Review
• Opinion
• Original Research
• Perspective
• Review
• Systematic Review
• Technology and Code

Keywords: antibody drug conjugates, Immunotherapy, Therapy Resistance, Combination Therapy, Biomarkers

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.